Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of August 14, 2025 • 9:01 PM ET

Date/Time Source News Release
08/13/2025 04:30 PM EDT Business Wire Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
08/06/2025 08:30 AM EDT Business Wire Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
08/04/2025 08:55 AM EDT Business Wire Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai(TM)
07/31/2025 07:30 AM EDT Business Wire Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic(TM) Clinical Trial in Japan for LP-300
07/28/2025 08:00 AM EDT Business Wire Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
07/23/2025 07:56 AM EDT Business Wire Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
07/21/2025 08:20 AM EDT Business Wire Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
07/16/2025 08:30 AM EDT GlobeNewswire IBN Initiates Coverage of Lantern Pharma Inc.
07/15/2025 09:40 AM EDT Business Wire Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
06/16/2025 08:30 AM EDT Business Wire Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
Page

Additional News

As of August 14, 2025 • 9:01 PM ET

Date/Time Source News Release
08/14/2025 10:10 AM EDT AINewsWire AINewsBreaks - Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform
08/14/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, August 14th, 2025
08/14/2025 05:31 AM EDT US Earnings Reports Expected earnings - Lantern Pharma Inc.
08/13/2025 06:45 PM EDT KlickAnalytics LTRN - Historical Price Movements Surrounding Earnings
08/13/2025 06:40 PM EDT KlickAnalytics LTRN - Historical Earnings Price Analysis
08/13/2025 04:43 PM EDT SeekingAlpha Lantern Pharma GAAP EPS of -$0.40 beats by $0.08
08/07/2025 09:05 AM EDT BioMedWire Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
08/06/2025 12:15 PM EDT AINewsWire Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations
08/06/2025 10:37 AM EDT BioMedWire BioMedNewsBreaks - Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial 
08/04/2025 09:35 AM EDT AINewsWire AINewsBreaks - Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.